UTHR Stock Forecast 2025-2026
Distance to UTHR Price Targets
UTHR Price Momentum
10 Quality Stocks Worth Considering Now
Researching United Therapeutics (UTHR) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on UTHR and similar high-potential opportunities.
Latest UTHR Stock Price Targets & Analyst Predictions
Based on our analysis of 19 Wall Street analysts, UTHR has a bullish consensus with a median price target of $395.00 (ranging from $293.00 to $600.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $310.82, the median forecast implies a 27.1% upside. This outlook is supported by 9 Buy, 5 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Hartaj Singh at Oppenheimer, projecting a 93.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
UTHR Analyst Ratings
UTHR Price Target Range
Latest UTHR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for UTHR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 27, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $425.00 |
| Jan 8, 2025 | UBS | Ashwani Verma | Buy | Maintains | $475.00 |
| Nov 1, 2024 | Goldman Sachs | Chris Shibutani | Neutral | Maintains | $302.00 |
| Oct 31, 2024 | Ladenburg Thalmann | Matthew Kaplan | Buy | Maintains | $344.00 |
| Oct 31, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $425.00 |
| Oct 31, 2024 | Oppenheimer | Hartaj Singh | Outperform | Maintains | $600.00 |
| Oct 31, 2024 | Argus Research | Jasper Hellweg | Buy | Maintains | $400.00 |
| Oct 21, 2024 | TD Cowen | Joseph Thome | Buy | Maintains | $400.00 |
| Sep 23, 2024 | Jefferies | Eun Yang | Buy | Maintains | $432.00 |
| Aug 28, 2024 | Oppenheimer | Hartaj Singh | Outperform | Maintains | $575.00 |
| Aug 20, 2024 | Wells Fargo | Tiago Fauth | Overweight | Maintains | $380.00 |
| Aug 1, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $400.00 |
| Aug 1, 2024 | B of A Securities | Greg Harrison | Underperform | Maintains | $280.00 |
| Jul 25, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $400.00 |
| Jul 11, 2024 | Morgan Stanley | Terence Flynn | Equal-Weight | Downgrade | $321.00 |
| Jul 11, 2024 | TD Cowen | Joseph Thome | Buy | Maintains | $350.00 |
| Jul 8, 2024 | UBS | Ashwani Verma | Buy | Maintains | $370.00 |
| Jun 12, 2024 | Wells Fargo | Tiago Fauth | Overweight | Maintains | $350.00 |
| May 21, 2024 | JP Morgan | Jessica Fye | Overweight | Maintains | $300.00 |
| May 3, 2024 | Goldman Sachs | Chris Shibutani | Neutral | Maintains | $240.00 |
United Therapeutics Corporation (UTHR) Competitors
The following stocks are similar to United Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
United Therapeutics Corporation (UTHR) Financial Data
United Therapeutics Corporation has a market capitalization of $13.96B with a P/E ratio of 12.6x. The company generates $2.88B in trailing twelve-month revenue with a 41.5% profit margin.
Revenue growth is +19.7% quarter-over-quarter, while maintaining an operating margin of +49.2% and return on equity of +19.2%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
United Therapeutics Corporation (UTHR) Business Model
About United Therapeutics Corporation
Develops innovative pharmaceutical products for critical conditions.
The company generates revenue through the development and commercialization of therapies for chronic and life-threatening conditions, particularly focusing on pulmonary arterial hypertension. By offering a range of products, including both oral and inhaled treatments, United Therapeutics addresses unmet medical needs and enhances patient quality of life, thereby driving sales and market growth.
Headquartered in Silver Spring, Maryland, United Therapeutics is involved in all stages of drug research, from clinical trials to post-market analysis. The company is also investing in advanced technologies such as organ manufacturing and regenerative medicine, indicating a long-term commitment to innovation in healthcare.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
1,305
CEO
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
Country
United States
IPO Year
1999
Website
www.unither.comUnited Therapeutics Corporation (UTHR) Latest News & Analysis
United Therapeutics Corporation to Present at the Leerink Partners Global Healthcare Conference 2025
23 days agoUnited Therapeutics (Nasdaq: UTHR) CFO James Edgemond will discuss company operations at the Leerink Partners Global Healthcare Conference on March 11, 2025, from 10:00-10:30 AM EDT.
United Therapeutics' CFO will discuss company operations at a major healthcare conference, potentially impacting investor sentiment and stock performance based on insights shared.
United Therapeutics Corporation (NASDAQ: UTHR) will hold its Q4 2024 earnings conference call on February 26, 2025, at 9:00 AM ET, featuring key executives.
The Q4 2024 earnings conference call for United Therapeutics will provide insights into the company's financial performance and strategic direction, influencing investor sentiment and stock valuation.
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results
1 month agoUnited Therapeutics reported record revenues of $2.88 billion for 2024, a 24% increase from 2023, marking the third consecutive year of revenue growth.
United Therapeutics reported a strong 24% revenue growth to $2.88 billion for 2024, indicating robust business performance and potential for future profitability, which may boost investor confidence.
United Therapeutics (UTHR) reported Q3 earnings of $6.19 per share, surpassing the Zacks estimate of $6.10 and up from $4.36 per share year-over-year.
United Therapeutics' earnings beat expectations and show significant growth year-over-year, indicating strong financial performance and potential for future investment interest.
United Therapeutics (UTHR) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
1 month agoUnited Therapeutics (UTHR) reported revenue and EPS for Q4 2024. Investors should compare these figures with Wall Street estimates and year-ago performance for context.
Comparing UTHR's revenue and EPS to estimates and prior year figures reveals growth potential or weaknesses, impacting stock valuation and investor sentiment.
UTHR reported fourth-quarter earnings and sales that exceeded estimates, but Tyvaso sales did not meet expectations.
UTHR's earnings and sales beat expectations, suggesting strong overall performance, while Tyvaso's underperformance raises concerns about future growth potential.
Frequently Asked Questions About UTHR Stock
What is United Therapeutics Corporation's (UTHR) stock forecast for 2025?
Based on our analysis of 19 Wall Street analysts, United Therapeutics Corporation (UTHR) has a median price target of $395.00. The highest price target is $600.00 and the lowest is $293.00.
Is UTHR stock a good investment in 2025?
According to current analyst ratings, UTHR has 9 Buy ratings, 5 Hold ratings, and 1 Sell ratings. The stock is currently trading at $310.82. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for UTHR stock?
Wall Street analysts predict UTHR stock could reach $395.00 in the next 12 months. This represents a 27.1% increase from the current price of $310.82. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is United Therapeutics Corporation's business model?
The company generates revenue through the development and commercialization of therapies for chronic and life-threatening conditions, particularly focusing on pulmonary arterial hypertension. By offering a range of products, including both oral and inhaled treatments, United Therapeutics addresses unmet medical needs and enhances patient quality of life, thereby driving sales and market growth.
What is the highest forecasted price for UTHR United Therapeutics Corporation?
The highest price target for UTHR is $600.00 from Hartaj Singh at Oppenheimer, which represents a 93.0% increase from the current price of $310.82.
What is the lowest forecasted price for UTHR United Therapeutics Corporation?
The lowest price target for UTHR is $293.00 from at , which represents a -5.7% decrease from the current price of $310.82.
What is the overall UTHR consensus from analysts for United Therapeutics Corporation?
The overall analyst consensus for UTHR is bullish. Out of 19 Wall Street analysts, 9 rate it as Buy, 5 as Hold, and 1 as Sell, with a median price target of $395.00.
How accurate are UTHR stock price projections?
Stock price projections, including those for United Therapeutics Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
